Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Recruiting now · Phase 1
Conditions studied: Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor, GIST
In brief
The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to \<18 years of age with somatostatin receptor (SSTR)-positive tumors.
Key facts
- Study ID
- NCT06441331
- Run by
- ITM Solucin GmbH
- People needed
- 20
- Starts
- 2025-09-26
- Expected to finish
- 2034-04-01
- Last updated by the study team
- 2026-08-04
Who can join
Age: 2 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Benioff Children's Hospital — San Francisco, California, United States (enrolling)
- The Children's Hospital of Philadelphia (CHOP) — Philadelphia, Pennsylvania, United States (enrolling)
- University of Texas - MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Gustave Roussy Cancer Campus — Villejuif, France (enrolling)
- Hospital Universitario Vall d'Hebron - Oncología Médica — Barcelona, Spain (enrolling)
- Hospital General Universitario Gregorio Marañón — Madrid, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.